SIRS-Lab Commences Clinical Trial for PCR-Array-Based Sepsis Test
March 24, 2011
SIRS-Lab Commences Clinical Trial for PCR-Array-Based Sepsis Test
German molecular diagnostics firm SIRS-Lab this week commenced a 1,000-patient clinical study in its home country to evaluate Vyoo, the company's PCR- and microarray-based molecular test for causative agents of sepsis. Results from the study will support an application for regulatory approval in Europe.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Analytik Jena Buys Assets of Insolvent MDx Firm SIRS-Lab
May 6, 2013 / GenomeWeb Daily News - Dx Focus: BD MAX MRSA; SIRS-Lab Sepsis Test
August 16, 2012 / PCR Insider - Eppendorf Licenses Thermal Gradient IP to Analytik Jena
January 5, 2012 / PCR Insider - Seegene Using Molzym DNA-Enrichment Tech for Multiplex PCR Sepsis Test
March 24, 2011 / PCR Insider - Germany's Magna Diagnostics Heading Development of Point-of-Care Molecular Testing Platform
January 6, 2011 / PCR Insider